FDA to Review Baloxavir sNDA for Patients at High-Risk for Flu Complications
The Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil; Genentech) for the treatment of influenza in patients at high risk of complications.
